Resverlogix Corp. (TSE:RVX – Get Free Report) rose 16.7% on Wednesday . The company traded as high as C$0.07 and last traded at C$0.07. Approximately 197,830 shares traded hands during trading, an increase of 225% from the average daily volume of 60,927 shares. The stock had previously closed at C$0.06.
Resverlogix Stock Performance
The business has a fifty day simple moving average of C$0.07 and a 200 day simple moving average of C$0.06. The company has a market cap of C$18.00 million, a P/E ratio of -1.20 and a beta of 0.77.
Resverlogix (TSE:RVX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported C($0.02) earnings per share (EPS) for the quarter. Equities research analysts expect that Resverlogix Corp. will post -0.22 EPS for the current year.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Read More
- Five stocks we like better than Resverlogix
- Financial Services Stocks Investing
- 3 Momentum Trades for October With Ample Upside Ahead
- Top Biotech Stocks: Exploring Innovation Opportunities
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- What Is WallStreetBets and What Stocks Are They Targeting?
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
